Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Regeneron Pharmaceuticals, Inc., widely known simply as Regeneron, is a leading US-headquartered biotechnology company established in 1988. With its primary base in Tarrytown, New York, and significant operational regions including Ireland, it operates within the critical pharmaceutical preparation manufacturing industry.
At its core, Regeneron focuses on discovering, developing, and commercialising transformative medicines for people with serious diseases. Its unique, science-driven approach leverages proprietary technologies like the VelociSuite platform to generate innovative treatments across diverse therapeutic areas, including ophthalmology, oncology, immunology, and rare diseases.
As a prominent player in the global pharmaceutical market, Regeneron has earned a reputation for pioneering scientific research and addressing unmet medical needs. The company's commitment to advancing human health through novel therapies solidifies its position as an industry innovator.
+32 vs industry average
Regeneron’s score of 74 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Regeneron's Carbon Emissions & Climate Commitments
In 2025, pharmaceutical preparation manufacturer Regeneron reported total global carbon emissions of approximately 1.23 billion kg CO2e. This included roughly 89.99 million kg CO2e from Scope 1 emissions, about 35.02 million kg CO2e from market-based Scope 2 emissions, and approximately 1.10 billion kg CO2e from Scope 3 emissions.
Looking at previous years, Regeneron's total emissions were approximately 1.47 billion kg CO2e in 2024, 972.38 million kg CO2e in 2023, and 783.54 million kg CO2e in 2022.
Regeneron is committed to reducing its environmental impact. The company has set a near-term intensity target to reduce its combined Scope 1 and 2 (market-based) GHG emissions per square metre by 30% by 2025, using a 2016 peak baseline. Additionally, Regeneron aims to match 100% of its electricity consumption with certified renewable energy sources by 2035, demonstrating a long-term commitment to climate neutrality for its Scope 2 emissions. All reported emissions data and reduction targets originate directly from Regeneron Pharmaceuticals, Inc.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more